Stuttgart - Delayed Quote EUR
Ryvu Therapeutics SA (9Y4.SG)
7.39
-0.20
(-2.64%)
As of 10:19:05 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
77,968
77,968
46,860
38,946
10,358
Cost of Revenue
19,580
19,580
17,554
17,406
13,725
Gross Profit
58,388
58,388
29,306
21,540
-3,367
Operating Expense
180,360
180,360
126,681
91,034
76,996
Operating Income
-121,972
-121,972
-97,375
-69,494
-80,363
Net Non Operating Interest Income Expense
5,320
5,320
13,736
56
-381
Pretax Income
-111,138
-111,138
-92,112
-79,195
-78,962
Tax Provision
297
297
--
4,587
116
Net Income Common Stockholders
-111,435
-111,435
-92,112
-83,782
-79,078
Diluted NI Available to Com Stockholders
-111,435
-111,435
-92,112
-83,782
-79,078
Basic EPS
-4.80
-4.80
-4.00
-4.60
-4.30
Diluted EPS
-4.80
-4.80
-4.00
-4.60
-4.30
Basic Average Shares
23,120.15
23,120.15
22,898.23
18,355.47
18,355.47
Diluted Average Shares
23,120.15
23,120.15
22,898.23
18,355.47
18,355.47
Total Operating Income as Reported
-122,099
-122,099
-100,948
-78,422
-78,599
Total Expenses
199,940
199,940
144,235
108,440
90,721
Net Income from Continuing & Discontinued Operation
-111,435
-111,435
-92,112
-83,782
-79,078
Normalized Income
-116,982.69
-116,982.69
-92,112
-83,782
-79,078
Interest Income
9,128
9,128
13,833
1,145
61
Interest Expense
3,808
3,808
97
1,089
442
Net Interest Income
5,320
5,320
13,736
56
-381
EBIT
-107,330
-107,330
-92,015
-78,106
-78,520
EBITDA
-96,834
-96,834
-81,043
-65,206
-65,959
Reconciled Cost of Revenue
19,580
19,580
17,554
17,406
13,725
Reconciled Depreciation
10,495
10,495
10,972
12,900
12,561
Net Income from Continuing Operation Net Minority Interest
-111,435
-111,435
-92,112
-83,782
-79,078
Total Unusual Items Excluding Goodwill
6,849
6,849
--
1,195
--
Total Unusual Items
6,849
6,849
--
1,195
--
Normalized EBITDA
-103,683
-103,683
-81,043
-65,206
-65,959
Tax Rate for Calcs
0
0
--
0
0
Tax Effect of Unusual Items
1,301.31
1,301.31
--
--
--
12/31/2021 - 12/1/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade